Home / Healthcare / Pharma Mar, S.A. - Product Pipeline Review - 2015

Pharma Mar, S.A. - Product Pipeline Review - 2015

Published: Jul 2015 | No Of Pages: 44 | Published By: Global Markets Direct

Pharma Mar, S.A. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Pharma Mar, S.A. - Product Pipeline Review - 2015', provides an overview of the Pharma Mar, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharma Mar, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pharma Mar, S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pharma Mar, S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pharma Mar, S.A.'s pipeline products

Reasons to buy

- Evaluate Pharma Mar, S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pharma Mar, S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pharma Mar, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pharma Mar, S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharma Mar, S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pharma Mar, S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pharma Mar, S.A. Snapshot 5
Pharma Mar, S.A. Overview 5
Key Information 5
Key Facts 5
Pharma Mar, S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Pharma Mar, S.A. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pharma Mar, S.A. - Pipeline Products Glance 11
Pharma Mar, S.A. - Late Stage Pipeline Products 11
Pre-Registration Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Pharma Mar, S.A. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Pharma Mar, S.A. - Drug Profiles 15
trabectedin 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
lurbinectedin 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
plitidepsin 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
PM-060184 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Pharma Mar, S.A. - Pipeline Analysis 26
Pharma Mar, S.A. - Pipeline Products by Target 26
Pharma Mar, S.A. - Pipeline Products by Route of Administration 27
Pharma Mar, S.A. - Pipeline Products by Molecule Type 28
Pharma Mar, S.A. - Pipeline Products by Mechanism of Action 29
Pharma Mar, S.A. - Recent Pipeline Updates 30
Pharma Mar, S.A. - Dormant Projects 37
Pharma Mar, S.A. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
ES-285 38
elisidepsin 38
Pharma Mar, S.A. - Company Statement 39
Pharma Mar, S.A. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

Pharma Mar, S.A., Key Information 5
Pharma Mar, S.A., Key Facts 5
Pharma Mar, S.A. - Pipeline by Indication, 2015 7
Pharma Mar, S.A. - Pipeline by Stage of Development, 2015 9
Pharma Mar, S.A. - Monotherapy Products in Pipeline, 2015 10
Pharma Mar, S.A. - Pre-Registration, 2015 11
Pharma Mar, S.A. - Phase III, 2015 12
Pharma Mar, S.A. - Phase II, 2015 13
Pharma Mar, S.A. - Phase I, 2015 14
Pharma Mar, S.A. - Pipeline by Target, 2015 26
Pharma Mar, S.A. - Pipeline by Route of Administration, 2015 27
Pharma Mar, S.A. - Pipeline by Molecule Type, 2015 28
Pharma Mar, S.A. - Pipeline Products by Mechanism of Action, 2015 29
Pharma Mar, S.A. - Recent Pipeline Updates, 2015 30
Pharma Mar, S.A. - Dormant Developmental Projects,2015 37
Pharma Mar, S.A. - Discontinued Pipeline Products, 2015 38
Pharma Mar, S.A., Subsidiaries 42

Pharma Mar, S.A. - Pipeline by Top 10 Indication, 2015 7
Pharma Mar, S.A. - Pipeline by Stage of Development, 2015 9
Pharma Mar, S.A. - Monotherapy Products in Pipeline, 2015 10
Pharma Mar, S.A. - Pipeline by Top 10 Target, 2015 26
Pharma Mar, S.A. - Pipeline by Top 10 Route of Administration, 2015 27
Pharma Mar, S.A. - Pipeline by Top 10 Molecule Type, 2015 28
Pharma Mar, S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 29

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +